Irv Weissman (Norbert von der Groeben for Stanford)
March 12, 2020 06:55 AM EDTUpdated 08:39 AM
People
Deals

Stan­ford stem cell pi­o­neer nets $194M from Gilead-Forty Sev­en buy­out

Jason Mast

Editor

Gilead’s $4.9 bil­lion buy­out of Forty Sev­en, their largest in three years, brought with it a sub­stan­tial wind­fall for the biotech’s founder, CEO and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times